CHECKMATE-649

NCT02872116 📎

Regimen

Experimental
nivolumab + FOLFOX or XELOX
Control
FOLFOX or XELOX

Population

HER2-negative advanced gastric, GEJ, or esophageal adenocarcinoma as first-line therapy

Key finding

PD-L1 CPS>=5: mOS 14.4 vs 11.1 mo (HR 0.71, 98.4% CI 0.59-0.86, p<0.0001); mPFS 7.7 vs 6.0 mo (HR 0.68); ORR 60% vs 45%; primary endpoint met

Source: PMID 34102137

Timeline

    Guideline citations

    • NCCN GASTRIC (p.45)
    • CSCO GASTRIC 2025 (p.80)⚠️ OCR source